Table 4 Association between patient characteristics and disease activity at week three
From: Clinical disease activity in autoimmune rheumatic patients receiving COVID-19 vaccines
SLEDAI-Level n = 21 (%) | P-Value | DAS-Level n = 17 (%) | P-Value | |
|---|---|---|---|---|
Age | 21 (100.0) | 0.38 | 17 (100.0) | 0.69 |
Gender-female | 20 (95.2) | 0.39 | 14 (82.4) | 0.84 |
Hydroxychloroquine - yes | 21 (100.0) | 0.37 | 14 (82.4) | 0.30 |
Prednisolone- yes | 21 (100.0) | 0.38 | 16 (94.1) | 0.13 |
Methotrexate - yes | 2 (9.5) | 0.09 | 8 (47.1) | 0.17 |
Mycophenolate mofetil - yes | 2 (9.5) | 0.42 | 0 (0.0) | |
Azathioprine- yes | 12 (57.1) | 0.03* | 1 (5.9) | 0.78 |
Sulfasalazine - yes | 0 (0.0) | 2 (11.8) | 0.85 |